GSK PLC closed 24.32% short of its 52-week high of £18.24, which the company achieved on May 16th.

CORE EARNINGS PER SHARE FORECAST: Fourth-quarter core earnings per share is expected to fall to 20.6 pounds from 28.9 pounds the year earlier, according to Visible Alpha. Shares in GSK are 3.6% up ...

On Monday, GSK plc (GSK) stock saw a decline, ending the day at $34.9 which represents a decrease of $-0.37 or -1.05% from the prior close of $35.27. The stock opened at $34.87 and touched a low of ...

Bearish flow noted in GSK (GSK) Pharma with 1,131 puts trading, or 2x expected. Most active are Mar-25 33 puts and Jan-26 35 puts, with total volume in those strikes near 730 contracts. The Put/Call ...

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

In 2000, the Union for International Cancer Control (UICC) named Feb. | In 2000, the Union for International Cancer Control named Feb. 4 World Cancer Day, with a goal of raising awareness of cancer ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...